Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome

What is the purpose of this trial?

This is an investigator-initiated proof of concept study with the purpose to examine the safety, tolerability and feasibility of Dronabinol (synthetic Δ9-THC) and PEA for the treatment of adults with Tourette syndrome.


Participation Guidelines

Ages: 18 - 60 years

Gender: Both


Therapix Biosciences Ltd.

Start Date: 02/20/2017

End Date: 01/31/2018

Last Updated: 02/22/2018

Study HIC#: 1610018525

Get Involved

For more information about this study, contact:
Angie Landeros-Weisenberger
+1 203-737-4809
angeli.landeros@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Michael Howard Bloch

Principal Investigator

Sub-Investigators